A Secondary Analysis of the Exenatide-PD Trial

[Farooqji]

In this seconday analysis of a randomized clinical trial, serum samples from 60 participants in the Exenatide-PD trial were used to isolate neuronal-derived exosomes to evaluate levels of the brain insulin-signaling proteins and downstream effectors protein kinase B (Akt) and mechanistic target of rapamycin. After 48 and 60 weeks of subcutaneous drug administration, patients with Parkinson disease treated with exenatide had greater activation of brain insulin signaling proteins and downstream effectors compared with baseline and patients in the placebo group.

jamanetwork.com/journals/ja...

[Prakash1]

I've read articles about Exenetide which are very encouraging

[jeffreyn]

The paper and the editorial are available on the CPT website:

cureparkinsons.org.uk/news/...